Elanco Animal Health (NYSE:ELAN – Get Free Report) and Appili Therapeutics (OTCMKTS:APLIF – Get Free Report) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, profitability, earnings, dividends, valuation, risk and analyst recommendations.
Risk & Volatility
Elanco Animal Health has a beta of 1.41, meaning that its share price is 41% more volatile than the S&P 500. Comparatively, Appili Therapeutics has a beta of -0.48, meaning that its share price is 148% less volatile than the S&P 500.
Analyst Ratings
This is a summary of recent ratings and price targets for Elanco Animal Health and Appili Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Elanco Animal Health | 1 | 4 | 4 | 0 | 2.33 |
| Appili Therapeutics | 0 | 0 | 0 | 0 | 0.00 |
Insider and Institutional Ownership
97.5% of Elanco Animal Health shares are held by institutional investors. 0.6% of Elanco Animal Health shares are held by company insiders. Comparatively, 11.8% of Appili Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Profitability
This table compares Elanco Animal Health and Appili Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Elanco Animal Health | 4.60% | 6.78% | 3.03% |
| Appili Therapeutics | -450.64% | N/A | -171.15% |
Earnings & Valuation
This table compares Elanco Animal Health and Appili Therapeutics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Elanco Animal Health | $4.42 billion | 1.40 | -$1.23 billion | $0.40 | 31.20 |
| Appili Therapeutics | $630,000.00 | N/A | -$2.80 million | ($0.02) | -1.16 |
Appili Therapeutics has lower revenue, but higher earnings than Elanco Animal Health. Appili Therapeutics is trading at a lower price-to-earnings ratio than Elanco Animal Health, indicating that it is currently the more affordable of the two stocks.
Summary
Elanco Animal Health beats Appili Therapeutics on 10 of the 12 factors compared between the two stocks.
About Elanco Animal Health
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.
About Appili Therapeutics
Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a taste-masked liquid oral suspension formulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paromomycin in Phase III clinical trials for the treatment of cutaneous leishmaniasis and disfiguring skin infections; and ATI-1701, which is a live-attenuated vaccine in preclinical trials for Francisella tularensis. The company was incorporated in 2015 and is headquartered in Halifax, Canada.
Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.
